Global Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Forecast 2023-2030- Product Image

Sale

Global Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Forecast 2023-2030

Report
192 Pages
March 2024
Region: Global
360iResearch™
ID: 5896414

UP TO €850EUR$875USD£733GBP OFF until Dec 31^st 2024

The Branded Generics Market size was estimated at USD 378.58 billion in 2022, USD 432.30 billion in 2023, and is expected to grow at a CAGR of 14.60% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts. Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector. There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Branded Generics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Branded Generics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s.

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Trade Named Generics
- Value-Added
Drug Type
- Alkylating Agents
- Anti-depressants
- Anti-epileptics
- Anti-hypertensive
- Anti-psychotics
- Antimetabolites
- Hormones
- Lipid Lowering Drugs
Route of Administration
- Oral
- Parenteral
- Topical
Indication
- Acute & Chronic Pain
- Cardiovascular Diseases
- Dermatological Diseases
- Gastrointestinal Diseases
- Neurological Diseases
- Oncology
Distribution Channel
- Offline
  - Hospital Pharmacy
  - Retail Pharmacy
- Online

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Branded Generics Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Branded Generics Market?
What are the technology trends and regulatory frameworks in the Branded Generics Market?
What is the market share of the leading vendors in the Branded Generics Market?
Which modes and strategic moves are suitable for entering the Branded Generics Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Branded Generics Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
5.1.2. Restraints
5.1.2.1. Concerns associated with quality variations in branded generic medications
5.1.3. Opportunities
5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
5.1.4. Challenges
5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
5.2. Market Segmentation Analysis
5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
5.3. Market Trend Analysis
5.3.1. Availability of well-structured standards for branded generics in the Americas
5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Branded Generics Market, by Product

6.1. Introduction
6.2. Trade Named Generics
6.3. Value-Added

7. Branded Generics Market, by Drug Type

7.1. Introduction
7.2. Alkylating Agents
7.3. Anti-depressants
7.4. Anti-epileptics
7.5. Anti-hypertensive
7.6. Anti-psychotics
7.7. Antimetabolites
7.8. Hormones
7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical

9. Branded Generics Market, by Indication

9.1. Introduction
9.2. Acute & Chronic Pain
9.3. Cardiovascular Diseases
9.4. Dermatological Diseases
9.5. Gastrointestinal Diseases
9.6. Neurological Diseases
9.7. Oncology

10. Branded Generics Market, by Distribution Channel

10.1. Introduction
10.2. Offline
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3. Online

11. Americas Branded Generics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Branded Generics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Zentiva Completes Major Product Acquisition From Tillomed Spain
14.3.1.2. Procaps Group to Acquire Grupo Somar from Advent International
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
14.3.3. New Product Launch & Enhancement
14.3.3.1. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
14.3.3.2. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
14.3.3.3. Cipla Launches ‘Easylax L’,A Sugar-Free Oral Emulsion Laxative For Constipation Relief
14.3.4. Award, Recognition, & Expansion
14.3.4.1. Vyvanse Generics Approved by FDA
14.3.4.2. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
14.3.4.3. Dr Reddy’s Enters Trade Generics Business In Domestic Market

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Ajanta Pharma Ltd.
15.1.3. Alkem Laboratories Ltd.
15.1.4. Amneal Pharmaceuticals LLC
15.1.5. Apotex Inc.
15.1.6. Aspen Pharmacare Holdings Limited
15.1.7. AstraZeneca PLC
15.1.8. Aurobindo Pharma Limited
15.1.9. Bausch Health Companies Inc.
15.1.10. Bristol-Myers Squibb Company
15.1.11. Cipla Limited
15.1.12. Dr. Reddy’s Laboratories Ltd.
15.1.13. Endo International PLC
15.1.14. Eris Lifesciences Limited
15.1.15. Eva Pharma
15.1.16. Fresenius Kabi AG
15.1.17. GlaxoSmithKline PLC
15.1.18. Glenmark Pharmaceuticals Limited
15.1.19. Hetero Drugs Limited
15.1.20. Lupin Limited
15.1.21. Micro Labs Limited
15.1.22. Nichi-Iko Pharmaceutical Co., Ltd.
15.1.23. Pfizer Inc.
15.1.24. Sandoz International GmbH by Novartis AG
15.1.25. Sanofi S.A.
15.1.26. Sun Pharmaceutical Industries Ltd.
15.1.27. Teva Pharmaceutical Industries Ltd.
15.1.28. Torrent Pharmaceuticals Ltd.
15.1.29. Viatris Inc.
15.1.30. Zentiva Group, a.s.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
FIGURE 2. BRANDED GENERICS MARKET SIZE, 2022 VS 2030
FIGURE 3. BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BRANDED GENERICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. BRANDED GENERICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. BRANDED GENERICS MARKET DYNAMICS
FIGURE 7. BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 8. BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
FIGURE 10. BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 12. BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. BRANDED GENERICS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 14. BRANDED GENERICS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 16. BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 9. BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 31. BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 53. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 85. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 91. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 103. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 139. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 164. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 176. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. FRANCE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. GERMANY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 194. ITALY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 195. ITALY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 196. ITALY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. ITALY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. ITALY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. ITALY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. NORWAY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 218. POLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 219. POLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. POLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. POLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. POLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 224. QATAR BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 225. QATAR BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. QATAR BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. QATAR BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. QATAR BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. QATAR BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 248. SPAIN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. SPAIN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. SPAIN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 266. TURKEY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. TURKEY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. TURKEY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 284. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 285. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 286. BRANDED GENERICS MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Ajanta Pharma Ltd.
Alkem Laboratories Ltd.
Amneal Pharmaceuticals LLC
Apotex Inc.
Aspen Pharmacare Holdings Limited
AstraZeneca PLC
Aurobindo Pharma Limited
Bausch Health Companies Inc.
Bristol-Myers Squibb Company
Cipla Limited
Dr. Reddy’s Laboratories Ltd.
Endo International PLC
Eris Lifesciences Limited
Eva Pharma
Fresenius Kabi AG
GlaxoSmithKline PLC
Glenmark Pharmaceuticals Limited
Hetero Drugs Limited
Lupin Limited
Micro Labs Limited
Nichi-Iko Pharmaceutical Co., Ltd.
Pfizer Inc.
Sandoz International GmbH by Novartis AG
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Viatris Inc.
Zentiva Group, a.s.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	192
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 432.3 Billion
Forecasted Market Value ( USD ) by 2030	$ 1126.43 Billion
Compound Annual Growth Rate	14.6%
Regions Covered	Global
No. of Companies Mentioned	30

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3277EUR$3,374USD£2,827GBP €3641EUR$3,749USD£3,141GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4151EUR$4,274USD£3,581GBP €4613EUR$4,749USD£3,979GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5025EUR$5,174USD£4,335GBP €5584EUR$5,749USD£4,817GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5900EUR$6,074USD£5,089GBP €6555EUR$6,749USD£5,655GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7648EUR$7,874USD£6,598GBP €8498EUR$8,749USD£7,331GBP

Regional Insights

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Branded Generics Market Size, Share & Trends Analysis By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), By Application, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Branded Generics Global Market Report 2024

Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Global Branded Generics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Branded Generics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

About the Branded Generics Market